Option Care ha sido seleccionado como proveedor nacional de CUVITRU
By: Option Care
December 1, 2016
BANNOCKBURN, Ill., November 29, 2016 — Option Care Enterprises, Inc., one of the nation’s leading providers of home and alternate treatment site infusion services, has been selected as a contracted provider of a new 20% formulation of subcutaneous immunoglobulin (SCIG) therapy for primary immunodeficiency (PI). CUVITRU™ [Immune Globulin Subcutaneous (Human), 20% Solution] is manufactured by Shire plc.
CUVITRU™ recently was approved by the U.S. Food and Drug Administration to treat adult and pediatric patients two years and older with PI, a group of more than 300 genetic disorders in which part of the body’s immune system is missing or functions improperly.
“Option Care has a proven track record of providing compassionate, high-quality clinical care in the home or at alternate treatment sites to patients undergoing therapy for a variety of complex conditions, including those with primary immunodeficiency,” said Lisa Betts, Vice President, Specialty Programs, Option Care. “As one of the largest national providers of immunoglobulin therapy, we are pleased to offer CUVITRU™ to support primary immunodeficiency patients as we continue to spread awareness and improve treatment options. “
Immunoglobulin (IG) is a lifelong therapy provided to prevent recurrent infections in patients with PI, which affects as many as six million people worldwide.
Option Care cuenta con una plantilla de más de 1800 expertos clínicos, entre ellos, farmacéuticos y más de 1200 enfermeros de infusión. Este equipo multidisciplinario de profesionales clínicos capacitados especialmente proporciona planes personalizados de atención, monitoreo clínico de cada infusión y educación integral del paciente y del cuidador. Para obtener más información, llame al centro de excelencia de la especialidad IG de Option Care al 1-877-974-4844 o envíe un fax al 877-974-4845.
Acerca de Option Care
Option Care Enterprises, Inc. (Option Care) is one of the nation’s largest and most trusted providers of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all acute and chronic patients across the United States. Learn more at www.OptionCare.com.
###
You might also be interested in:
Estudio de Option Care concluye que pacientes que reciben atención de clínicos nutricionistas dedicados tienen probabilidades de beneficiarse de mejores resultados.
BANNOCKBURN, Ill., Jan. 22, 2018 — Option Care Enterprises, Inc., the nation’s largest independent provider of home and alternate site infusion services, is presenting data highlighting the importance of clinical excellence in nutrition support at the American Society for Parenteral and Enteral Nutrition (ASPEN) 2018 Nutrition Science & Practice Conference. Featured research includes an abstract […]
Option Care forma una coalición para defender a los pacientes vulnerables de Medicare que pierden la atención de infusión en el hogar
Calls on Congress to Fix Unintended Consequence of 21st Century Cures Act; Encourages Patients, Families, Others to Join Outreach BANNOCKBURN, Ill., Jan. 23, 2017 — Option Care is working diligently to persuade the U.S. Congress to fix a new law that has caused vulnerable Medicare patients to lose access to home infusion care, and is […]